Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

It is known that endothelial cells in the kidney are also strongly VEGF-dependent. Whether intravitreal drugs can be detected within the glomeruli or affect VEGF in glomerular podocytes is not known. Therefore, the aim of this pilot study was to investigate the effects of a single intravitreal injec...

Full description

Bibliographic Details
Main Authors:	Alexander Tschulakow, Sarah Christner, Sylvie Julien, Maximilian Ludinsky, Markus van der Giet, Ulrich Schraermeyer
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4240650?pdf=render

Similar Items

Efficacy of intravitreal injection of Aflibercept vs Ranibizumab in the treatment of diabetic retinopathy
by: Chang Huang, et al.
Published: (2021-05-01)

Effects of Intravitreal Injection of Ranibizumab and Aflibercept on Corneal Endothelium and Central Corneal Thickness
by: Mehmet Coskun
Published: (2018-08-01)

Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness
by: Jayoung Ahn, et al.
Published: (2021-03-01)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01)

Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells – comparison of in vivo analysis versus histological follow up
by: Alexander V. Tschulakow, et al.
Published: (2016-11-01)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
by: Beata Urban, et al.
Published: (2020-01-01)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
by: Fujii A, et al.
Published: (2014-06-01)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
by: Ali Demircan, et al.
Published: (2018-01-01)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
by: Norihiro Shimizu, et al.
Published: (2017-01-01)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
by: Miura M, et al.
Published: (2013-08-01)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
by: Kikushima Wataru, et al.
Published: (2020-01-01)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
by: Makri OE, et al.
Published: (2018-09-01)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
by: Wataru Kikushima, et al.
Published: (2020-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
by: Antoine Herbaut, et al.
Published: (2017-01-01)

The effects of anti-VEGF drugs on the retinal pigment epithelium and inner segment after intravitreal injection in the monkeys
by: Nan Su, et al.
Published: (2016-06-01)

Penetration, distribution, and elimination of remofuscin/soraprazan in Stargardt mouse eyes following a single intravitreal injection using pharmacokinetics and transmission electron microscopic autoradiography: Implication for the local treatment of Stargardt’s disease and dry age‐related macular degeneration
by: Sylvie Julien‐Schraermeyer, et al.
Published: (2020-12-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
by: Sakanishi Y, et al.
Published: (2017-05-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)

Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model
by: Christoforidis, John Byron, et al.
Published: (2017)

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection
by: Elcin Suren, et al.
Published: (2020-01-01)

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
by: Alireza Lashay, et al.
Published: (2020-01-01)

Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
by: Vasumathy Vedantham
Published: (2019-01-01)

Result of intravitreal aflibercept injection for myopic choroidal neovascularization
by: Shih-Lin Chen, et al.
Published: (2021-09-01)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
by: Kanra, Ayse Yagmur, et al.
Published: (2018-12-01)

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
by: Hisashi Matsubara, et al.
Published: (2016-04-01)

Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
by: Yamashita M, et al.
Published: (2014-02-01)

Efficacy of single intravitreal injection of Ranibizumab for diabetic macular edema
by: Yu-Dong Fu, et al.
Published: (2017-03-01)

Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real life ELU study
by: Frederic Queguiner, et al.
Published: (2020-02-01)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
by: Hirakata T, et al.
Published: (2016-05-01)

Erratum: Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
by: .
Published: (2019-01-01)

Retinal pigment epithelium tear after intravitreal aflibercept injection
by: Saito M, et al.
Published: (2013-06-01)

Single Intravitreal Aflibercept Injection for Unilateral Acute Nonarteritic Ischemic Optic Neuropathy
by: Ziya Ayhan, et al.
Published: (2015-01-01)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
by: Sumit Randhir Singh, et al.
Published: (2018-01-01)

Severe Gemella haemolysans endophthalmitis following ranibizumab intravitreal injection
by: Silvia Olivia Salceanu, et al.
Published: (2017-01-01)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
by: James G. Wong, et al.
Published: (2017-04-01)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
by: Shinichiro Chujo, et al.
Published: (2020-09-01)